Jun 2026 (Q2 FY26) — Aug 12, 2026
Marchex Q2 FY26 — Arcania Acquisition Drives AI-Powered Solution Expansion and Strong Q3 Outlook
Read the full callMarchex earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 11.0 | −5.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -3.1 | +1.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -0.41 | −580.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
1Y: $1.82 on 17 Oct 2025 → $1.26. High $1.9 (3 Aug 2026), low $1.22 (15 Oct 2026).
Overview
Call summaries
Marchex Q2 FY26 — Arcania Acquisition Drives AI-Powered Solution Expansion and Strong Q3 Outlook
Read the full callEvery analysed call
Financials
Net profit, year on year: −580% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 12 | 11 | 12 | 12 | 11 | 11 | 11 |
| Expenses | 13 | 14 | 13 | 12 | 12 | 13 | 12 | 11 |
| Operating profit | -1 | -2 | -2 | -1 | -1 | -2 | -1 | -0 |
| Operating margin | −6.6% | −13.3% | −16.4% | −4.6% | −8.2% | −21.9% | −12.7% | −3.1% |
| Profit before tax | -1 | -2 | -2 | 0 | -1 | -2 | -2 | -0 |
| Tax rate | −3.1% | −18.1% | −5.8% | 5.6% | −2.7% | 2.6% | −13.1% | −37.4% |
| Net profit | -1 | -2 | -2 | 0 | -1 | -2 | -2 | -0 |
| EPS ($ per share) | -0.02 | — | -0.05 | 0 | -0.02 | — | -0.04 | -0.01 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -256 | -260 | -299 | -303 | -311 | -321 | -326 | -331 |
| Total liabilities | 18 | 25 | 24 | 14 | 13 | 12 | 11 | 10 |
| Fixed assets | 3 | 3 | 3 | 3 | 4 | 2 | 2 | 2 |
| Total assets | 113 | 125 | 77 | 66 | 57 | 47 | 43 | 40 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5 | 5 | -3 | -6 | -2 | -4 | -1 | -1 |
| Cash from investing | -37 | -10 | 1 | -1 | -3 | -1 | -0 | -1 |
| Cash from financing | -27 | 2 | -5 | 1 | -1 | -0 | -0 | -0 |
| Net cash flow | -59 | -3 | -8 | -7 | -7 | -6 | -2 | -3 |
| Capital expenditure | -2 | -2 | -1 | -1 | -3 | -1 | -0 | -0 |
| Free cash flow | 3 | 3 | -5 | -8 | -5 | -6 | -1 | -1 |
3 filings, all on Mar 20, 2026.
Nobody bought or sold MCHX on the open market in this window. The filings below are 3 option exercises.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Mar 20, 2026 | Feeney Francis J Chief Operating Officer & CLO | Option exercise | 62,500 | — |
| Mar 20, 2026 | Nagle Brian Chief Financial Officer | Option exercise | 7,500 | — |
| Mar 20, 2026 | HARTLESS TROY President & Chief Rev Officer | Option exercise | 87,500 | — |
| Mar 27, 2025 | Edenbrook Capital, LLC 10% owner | Purchase | 2,316 | $3.9K |
| Mar 26, 2025 | Edenbrook Capital, LLC 10% owner | Purchase | 30,962 | $52.8K |
| Mar 25, 2025 | Edenbrook Capital, LLC 10% owner | Purchase | 69,197 | $121.1K |
| Nov 18, 2024 | Miller Edwin A Chief Executive Officer | Purchase 10b5-1 plan | 4,980 | $8.6K |
| Nov 15, 2024 | Miller Edwin A Chief Executive Officer | Purchase 10b5-1 plan | 807 | $1.4K |
| Nov 14, 2024 | Miller Edwin A Chief Executive Officer | Purchase | 100,000 | $172.7K |
| Nov 13, 2024 | Miller Edwin A Chief Executive Officer | Purchase | 5,571 | $9.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow MARCHEX INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading